Skip to content
Search
Please enter at least 3 characters.

Latest Stories

164 pathfinder sites sign up to trial independent prescribing

164 pathfinder sites sign up to trial independent prescribing

The most common prescribing service is for minor ailments and it will be offered at 93 pathfinder sites.  

All 42 integrated care boards (ICBs) in England have signed memorandums of understanding for the NHS Independent Prescribing Pathfinder programme, the first nationally-funded prescribing service in the country.


Anne Joshua, interim deputy director of pharmacy commissioning at NHS England, made the revelation during the ‘Chief pharmaceutical officer bi-monthly webinar’ held on 7 March 2024, as reported by The Pharmaceutical Journal.

In the initial phase of the programme, 210 community pharmacies across all ICBs will trial independent prescribing, ahead of establishing a commissioning framework for the service.

Giving an update on the pathfinder programme, Joshua confirmed that 164 of these potential pathfinder sites had registered for the programme as of 29 February 2024.

Additionally, she announced the clinical models to be followed by the participating pharmacies and presented a graph showing an overview of the services they will provide.

The graph indicated minor ailments as the most common prescribing service, which will be offered by 93 community pharmacies. Hypertension, identified as the second most common service, will be offered at 73 independent prescribing pathfinder sites.

Respiratory services and cardiovascular disease prevention services (including lipids) will each be offered by 23 sites, contraception by 20 sites and dermatology by 12 sites.

The programme will see some sites offering novel services like prescription management being offered by 11 sites, women’s health by 10 sites, deprescribing by 8 sites, depression by 8 sites, anticoagulation by 5 sites, sexual health by 3 sites and health inequalities by 3 sites.

The pathfinders, initially slated for launch in January 2023, faced delays due to funding and implementation issues.

The Royal Pharmaceutical Society's official journal reported in February that Cleo Systems, the electronic prescribing system (EPS) provider, was working closely with NHS England to implement the pathfinder programme by spring 2024.

North of England Commissioning Support (NECS) has awarded a £285,000 contract to six suppliers to identify 10 pathfinder sites for North East and North Cumbria (NENC) ICB. The contract starts on 1 April 2024 and ends on 30 September 2024.

The contract summary published by the NECS on 15 March 2024 reads: “The pathfinder sites in NENC will be involved in exciting work to explore how community pharmacists can best deliver an integrated prescribing offer, for acute illnesses, alongside general practices in their local community.”

The six suppliers commissioned by NENC ICB to provide sites for the pathfinder programme are AK Medical Consultancy Ltd, Boots, Chemcare Ltd, Farah Chemists Ltd, M.D & A.G Burdon Ltd and Welcome Health Pharmacies Limited.

The NHS Pathfinder Programme aims to establish a framework for commissioning community pharmacy clinical services that incorporate independent prescribing for patients.

More For You

Imported dengue reach record high, warns UKSHA

Most dengue cases were linked to travel to Southern and South-Eastern Asia.

Getty Images

Imported dengue cases hit record high – Consult your pharmacist before you travel

The UK Health Security Agency (UKSHA) has warned that imported dengue cases in England, Wales, and Northern Ireland (EWNI) have reached their highest level since dengue surveillance began in 2009.

New data from the agency reveals that 904 dengue cases were reported among returning travellers in these countries in 2024, a sharp increase from 631 in 2023.

Keep ReadingShow less
Henry Gregg named as new NPA chief executive

Henry Gregg (left) with Sir Chris Whitty

Pic credit: Henry Gregg/X

Henry Gregg named as new NPA chief executive

The National Pharmacy Association (NPA) has announced Henry Gregg will be the organisation’s new chief executive from May.

Gregg, who is currently director of external affairs at Asthma + Lung UK, replaces Paul Rees who departed in January.

Keep ReadingShow less
Kelso Pharma continues expansion with £140M funding boost

Kelso Pharma will use the funds to support further acquisitions and expand in the UK and Europe.

Getty Images

Kelso Pharma secures over £140m of acquisition funding

Kelso Pharma has secured more than £140 million of acquisition funding to support its expansion in the UK and across Europe.

The specialty pharmaceuticals business today (27) confirmed that a proportion of the funding was used for its acquisition of ALTURiX last month, a deal that doubled the size of the company’s UK business.

Keep ReadingShow less
Community pharmacist accessing GP Connect Access Record on Cegedim Rx platform

GP Connect Access Record will make a patient’s relevant medical information available to pharmacy.

Getty Images

Cegedim Rx activates GP Connect Access Record

Community pharmacy IT supplier Cegedim Rx has made GP Connect Access Record functionality available across its clinical services platform, providing registered pharmacy professionals with enhanced access to patient medical information.

The new feature, now live on Cegedim Rx’s Pharmacy Services platform, allows community pharmacies to retrieve relevant medical data when delivering NHS clinical services.

Keep ReadingShow less
Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

Patients who purchase two prescriptions per month could save more than £110 annually with a 12-month PPC.

Getty Images

Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

The NHS Business Services Authority (NHSBSA) has published a new experimental analysis, estimating patient savings achieved from prescription prepayment certificates (PPCs), including Hormone Replacement Therapy (HRT) PPCs.

The report revealed that the number of Prescription Prepayment Certificates (PPCs) purchased has risen consistently over the past five years, with 3.3 million patients receiving NHS prescriptions under a PPC exemption in 2023/2024.

Keep ReadingShow less